SciSparc (SPRC) Restructuring Costs (2017 - 2018)
SciSparc's (SPRC) quarterly Restructuring Costs came in at $149000.0 in Q3 2018, down 33.78% year-over-year from $225000.0 in Q3 2017, and up 24.17% quarter-over-quarter from $120000.0 in Q2 2018.
Powered by 
Analysis
SciSparc (SPRC) Restructuring Costs (2017 - 2018) Analysis & Trends
SciSparc has disclosed Restructuring Costs across 2 years of filings, most recently posting $149000.0 for Q3 2018.
- In Q3 2018, Restructuring Costs fell 33.78% year-over-year to $149000.0; the TTM figure through Sep 2018 stood at $736000.0 (changed N/A YoY), while the FY2024 annual figure was $1.3 million, up 28.98% from the prior year.
- Restructuring Costs came in at $149000.0 for Q3 2018 at SciSparc, up from $120000.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $240000.0 in Q4 2017 to a low of $120000.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | SciSparc | 614,715.73 | 614,715.73 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2018 | 149,000.00 |
| Jun 30, 2018 | 120,000.00 |
| Mar 31, 2018 | 227,000.00 |
| Dec 31, 2017 | 240,000.00 |
| Sep 30, 2017 | 225,000.00 |
| Jun 30, 2017 | 185,000.00 |
| Mar 31, 2017 | 158,000.00 |